# Green Route for Efficient Synthesis of Novel Amino Acid Schiff Bases as Potent Antibacterial and Antifungal Agents and Evaluation of Cytotoxic Effects

Authors: Harshita Sachdeva; Rekha Saroj; Sarita Khaturia; Diksha Dwivedi; Om Prakash Chauhan
Journal: Journal of Chemistry
 (2014)

---

## Abstract

Green chemical one-pot multicomponent condensation reaction of substituted 1H-indole-2,3-diones (1), various amino acids (2), and thiosemicarbazide (3) is found to be catalyzed by lemon juice as natural acid using water as a green solvent to give the corresponding Schiff bases (4) in good to excellent  yields. This method is experimentally simple, clean, high yielding, and green, with reduced reaction times. The product is purified by simple filtration followed by washing with water and drying process. The synthesized compounds are characterized by FT-IR, 13CNMR, and 1HNMR spectroscopy and are screened for their antifungal activity against Aspergillus niger, Penicillium notatum, Fusarium oxysporum, Alternaria brassicicola, Chaetomium orium, and Lycopodium sp. and antibacterial activity against Gram-positive bacteria, Bacillus licheniformis, Staphylococcus aureus, and Micrococcus luteus, and Gram-negative bacteria, Pseudomonas aeruginosa and Escherichia coli. Compounds have also been evaluated for cytotoxic effects against human colon cancer cell line Colo205.


---

## Body

## 1. Introduction

In recent years, environmentally benign synthetic methods have received considerable attention and some green protocols have been developed [1, 2]. There has been a large emphasis both in the chemical industry and in academic research on the development of environmentally benign solvents and reaction conditions. Organic synthetic procedures use organic solvents like benzene and chlorinated hydrocarbons, which have created havoc to the environment because of their toxic and volatile nature [3, 4].To reduce such disasters there is a need to use a safer reaction medium like water. Water is nontoxic, safe, and cheap and never leads to menace to the environment [5–10]. The use of water as a solvent [11–13] is undoubtedly the best alternative as there are generally no harsh reaction conditions and no need of vigorous drying of the solvents.Schiff bases have been playing vital roles in the preparation of a large number of industrial and biologically active compoundsvia closure, cycloaddition, and replacement reactions. They are also known for their diversified biological activities such as anti-inflammatory, allergic inhibitors, radical scavenging, analgesic and antioxidative action, and so forth [14–16]. Further, the incorporation of oxindole nuclei is an important synthetic strategy in drug discovery. Oxindoles have shown an extensive range of biological effects, including antibacterial, antifungal, anticonvulsant, antiviral, and antiproliferative activity [17]. On the other hand, heterocyclic compounds possessing 1,3,4-thiadiazole ring system show antifungal, bacteriostatic, anthelmintic [18] effect as well as depression effect on central nervous system [19]. Palaska et al. [20] reported 1,3,4-thiadiazole derivatives that exhibited analgesic and anti-inflammatory activities.Considering the numerous applications of Schiff bases in various fields of chemistry, there has been tremendous interest in developing efficient methods for their preparation. Synthesis of Schiff base is often carried out with acid catalyst and generally by refluxing the mixture of aldehyde (or ketone) and amine in organic medium [21]. Classical organic synthesis of Schiff bases commonly meets the problem of removing solvents from the reaction mixture [22]. To overcome the difficulties in the removal of water, alternative method has been employed in which Lewis acid is used as catalyst which accelerates nucleophilic attack of amines on carbonyl carbon as well as serving as dehydrating agent for removal of the water. Several methods have been reported in the literature in which Lewis acids were used as catalysts such as ZnCl2 [23], TiCl4 [24], alumina [25], and P2O5 [26] and also by using materials like hydrotalcite [27]. Environmentally benign methods for the synthesis of Schiff bases have also been reported in the literature [28–32]. Although reported methodologies have their own advantages, they are overled by prolonged reaction time, the high reaction temperatures, an excess of costly dehydrating reagents/catalysts, moisture sensitive catalysts, special apparatus, and so forth.It has been observed that the incorporation of more than one bioactive heterocyclic moiety into a single framework may result in the production of novel heterocycles with enhanced bioactivity. Keeping in view the diverse biological activities associated with oxindole and thiadiazole, we have synthesized Schiff bases incorporating these moieties and the synthesized compounds were evaluated for their antibacterial, antifungal, and cytotoxic effects. Moreover, Schiff bases have been synthesized in aqueous medium under the framework of green chemistry in moderate to good yields and short reaction time. The condensation reaction occurs very efficiently in the presence of water and the product can be isolated simply by filtration without the need of any further purification.


## 2. Results and Discussion

In continuation of our work to develop green methodologies for the synthesis of organic compounds [33–36], herein we wish to report a mild and highly efficient procedure for the synthesis of 3-[1-(5-amino-[1,3,4]-thiadiazol-2-yl)substitutedethylimino]-5-substituted-2,3-dihydro-indol-2-one derivatives (4) using water as a green solvent and citric acid as a green catalyst (Scheme 1). 4 was synthesized by the one-pot multicomponent condensation reaction of substituted 1H-indole-2,3diones (1), various amino acids (2), and thiosemicarbazide (3) in the presence of lemon juice. The role of lemon juice in catalyzing the reaction was demonstrated by the lack of Schiff base formation when the reaction was carried out in the absence of catalyst. As lemon juice is acidic in nature (pH ≈ 2-3) and percentage of citric acid (5–7%) is more than other acids, it works as acid catalyst for Schiff base formation [37]. Using this methodology these reactions were completed in shorter reaction times (2-3 hrs) with yields of the product ranging from 70 to 86%. For the present reaction, we have used extract of Citrus limonum species of lemon as natural catalyst. The main ingredients of lemon juice are moisture (85%), carbohydrates (11.2%), citric acid (5–7%), protein (1%), vitamin C (0.5%), fat (0.9%), minerals (0.3%), fibers (1.6%), and some other organic acids.Scheme 1This green route method requires simple work-up procedure, that is, simple filtration to isolate the products as they are insoluble in water and the desired products are obtained with satisfactory yields without any further purification. Considering the reaction time with water as solvent and yield of products this process was selected as green, environmental benign, clean, and safe to promote the synthesis of various Schiff’s bases (Table1). This acceleration has been attributed to many factors, including the hydrophobic effect [38, 39], enhanced hydrogen bonding in the transition state [40], and the high cohesive energy density of water [41, 42].Table 1
Results of synthesis of4a–p in the presence of lemon juice as natural acid.
Entry
Product
Yield (%)
M.P. (°C)
Time (hrs)
Color
4a
86
195
2-3
Brown
4b
74
170
2-3
Brown
4c
78
103
2-3
Dark brown
4d
75
190
2-3
Dark brown
4e
74
170
2-3
Brown
4f
77
190
2-3
Brown
4g
70
98
2-3
Brown
4h
72
140
2-3
Red
4i
70
140
2-3
Yellow
4j
72
202
2-3
Orange
4k
77
190
2-3
Red
4l
73
180
2-3
Red
4m
85
210
2-3
Yellow
4n
76
203
2-3
Yellow
4o
72
130
2-3
Pale yellow
4p
74
212
2-3
Pale yellowInitially, we attempted to synthesize Schiff bases incorporating oxindole and 1,3,4-thiadiazole moieties in water by the reaction of1, 2, and3 in the presence of POCl3. Reaction gets completed in 5-6 hrs resulting in the formation of 4 with yields ranging from 60 to 70%. After the successful completion of reaction in water in the presence of POCl3, we decided to synthesize Schiff bases by employing lemon juice (2 mL) as green catalyst for green approach (Scheme 1) resulting in quantitative yield (70–86%) of the corresponding Schiff bases within 2 to 3 hrs. However, in the absence of lemon juice, spiro(indole-triazoles) are formed [43]. We have also carried out this reaction in the presence of citric acid but the yield of the product (4) was found to be low (60–70%) as compared to that carried out using lemon juice as a green catalyst (70–86%). All the synthesized compounds were found to be chiral [44]. The occurrence of E/Z isomerism at the imine band of the molecules was suggested by Sari and Gürkan [45].To establish the scope and limitations of lemon juice as a catalyst for Schiff base formation, structurally diverse 1H-indole-2,3-diones were treated with variously substituted amino acids under the catalytic influence of lemon juice and the results are summarized in Table 1. The purity of the compounds was checked by TLC using silica gel-G as adsorbent. The identity of the products obtained was confirmed by their IR, 13C NMR, and 1H NMR spectral studies. The stretching bands derived from –OH and C=O of carboxylic acid were disappeared with the appearance of new two bands at 3259 and 3157 cm−1 due to asymmetric and symmetric stretching vibrations of NH2 group. This evidence clearly confirmed the formation of compound 4.In summary, it can be stated that the present green synthetic protocol is highly efficient as it avoids the use of hazardous solvents at any stage of the reaction. As cited in Scheme1, not only does the use of water as solvent allow for rapid reactions, but also the products are often insoluble in water, facilitating their ready isolation.


## 3. Experimental Section

### 3.1. General

Reagents and solvents were obtained from commercial sources and used without further purification. Melting points were determined on a Toshniwal apparatus. The spectral analyses of synthesized compounds have been carried out at SAIF, Punjab University, Chandigarh. Purity of all compounds was checked by TLC using “G” coated glass plates and n-hexane : ethyl acetate (7 : 3) as eluent. IR spectra were recorded in KBr on a Perkin Elmer Infrared RXI FTIR spectrophotometer and1HNMR spectra were recorded on Bruker Avance II 400 NMR spectrometer using DMSO-d6 and CDCl3 as solvent and tetramethylsilane (TMS) as internal reference standard. The obtained products were identified from their spectral (1HNMR, 13C NMR, and IR) studies.


### 3.2. General Procedure for Extraction of Lemon Juice

Fresh lemon was cut by using knife and then pieces were pressed manually using domestic presser to extract juice. Then juice was then filtered through cotton/muslin cloth and then through filter paper to remove solid material and to get clear juice which was used as a catalyst.


### 3.3. Green Route for the Synthesis of 3-[1-(5-Amino-[1,3,4]-thiadiazol-2-yl)-substitutedethylimino]-5-substituted-2,3-dihydro-indol-2-ones (4a–p)

An equimolar mixture of substituted 1H-indole-2,3-diones (0.012 mol), amino acids (0.012 mol), and thiosemicarbazide in water (15 mL containing 1 mL of ethanol) in the presence of lemon juice (2 mL) was mixed in round bottom flask and the mixture was refluxed for the time needed to complete the reaction (as monitored by TLC). The initial syrupy reaction mixture solidifies within 2-3 hrs. After completion of reaction, mixture was cooled to room temperature and the solid mass obtained was filtered, washed with water, and dried. The desired products were obtained with satisfactory yields without any further purification.The spectroscopic characterization data of (4a–p) are given below.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-ethylimino]-2,3-dihydro-indol-2-one (
4a
). m.p. 195°C; IR (KBr): 3259, 3157, 2923, 1706, 1619, 1585, 1462, 673 cm−1; 1H NMR (DMSO-d6): 1.56 (d, 3H, CH3), 4.59 (q, 1H, CH), 7.03–7.67 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 23.8, 51.4, 120, 122, 124, 128, 132, 146.4, 162, 176, 178. Anal.calcd for C12H11N5OS: C, 52.73; H, 4.06; N, 25.62. Found: C, 52.91; H, 4.09; N, 25.63.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-3-methylsulfanyl-propylimino]-2,3-dihydro-indol-2-one (
4b
). m.p. 170°C; IR (KBr): 3263, 3177, 2980, 1706, 1620, 1580, 1462, 670 cm−1; 1H NMR (DMSO-d6): 2.09 (s, 3H, CH3), 2.31 (q, 2H, CH2), 2.44 (t, 2H, CH2), 4.41 (t, 1H, CH), 7.03–7.67 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 17, 30.4, 38.2, 52.4, 122, 124, 126, 128, 132, 146.2, 160, 172, 174. Anal.calcd for C14H15N5OS2: C, 50.43; H, 4.53; N, 21.00. Found: C, 50.24; H, 4.56; N, 21.02.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-(1H-imidazol-4-yl)-ethylimino]-2,3-dihydro-indol-2-one (
4c
). m.p. 103°C; IR (KBr): 3260, 3175, 2986, 1705, 1619, 1585, 1462, 673 cm−1; 1H NMR (DMSO-d6): 3.33 (d, 2H, CH2), 4.80 (t, 1H, CH), 6.80 (d, 1H, CH), 8.73 (d, 1H, CH), 7.03–7.67 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H), 13.4 (dd, 1H, NH) ppm. 13C-NMR (400 MHz, DMSO): 36, 56, 118, 120, 122.6, 124.8, 128.2, 132.2, 134.2, 136.8, 146.8, 162.8, 174.2, 176. Anal.calcd for C15H13N7OS: C, 53.09; H, 3.86; N, 28.89. Found: C, 53.27; H, 3.89; N, 28.91.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-(1H-indol-3-yl)-ethylimino]-2,3-dihydro-indol-2-one (
4d
). m.p. 190°C; IR (KBr): 3263, 3177, 2980, 1706, 1619, 1580, 1462, 670 cm−1; 1H NMR (DMSO-d6): 3.20 (d, 2H, CH2), 4.80 (t, 1H, CH), 7.18 (s 1H, CH), 10.85 (s, 1H, NH), 7.03–7.67 (m, 4H, aromatic), 6.97–7.58 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 36.8, 58, 110, 112, 118, 120.2, 122.8, 124, 128, 130.2, 132.6, 136, 146, 164.4, 176, 178.2. Anal.calcd for C20H16N6OS: C, 61.84; H, 4.15; N, 21.63. Found: C, 61.66; H, 4.18; N, 21.65.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-methylbutylimino]-2,3-dihydro-indol-2-one (
4e
). m.p. 170°C; IR (KBr): 3263, 3086, 2986, 2876, 1733, 1621, 1594, 1462, 673 cm−1; 1H NMR (DMSO-d6): 0.96 (t, 3H, CH3), 1.29 (q, 2H, CH2), 1.06 (d, 3H, CH3), 2.00 (m, 1H, CH), 4.40 (d, 1H, CH), 7.03–7.67 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 11.6, 15.8, 24.8, 38, 58.2, 120.2, 122.2, 124.8, 128, 132, 142.2, 162.2, 176.2, 178. Anal.calcd for C15H17N5OS: C, 57.12; H, 5.43; N, 22.21. Found: C, 57.32; H, 5.45; N, 22.23.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-methylpropylimino]-2,3-dihydro-indol-2-one (
4f
). m.p. 190°C; IR (KBr): 3260, 3150, 2877, 2803, 1695, 1620, 1580, 1465, 670 cm−1; 1H NMR (DMSO-d6): 1.01 (d, 3H, CH3), 1.01 (d, 3H, CH3), 2.2 (m, 1H, CH), 4.40 (d, 1H, CH), 7.03–7.67 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 18.2, 36.2, 78.6, 110, 126, 128, 130, 142, 143, 162.8, 176, 178.2. Anal.calcd for C14H15N5OS: C, 55.80; H, 5.02; N, 23.24. Found: C, 55.62; H, 5.04; N, 23.25.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-hydroxyethylimino]-2,3-dihydro-indol-2-one (
4g
). m.p. 98°C; IR (KBr): 3465, 3263, 3177, 2980, 1706, 1619, 1580, 1462, 673 cm−1; 1H NMR (DMSO-d6): 4.30 (d, 2H, CH2), 4.50 (t, 1H, CH), 4.78 (s, 1H, OH), 7.03–7.67 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 51.4, 68, 120, 122, 124, 128, 132, 146.2, 162.8, 176.2, 178.8. Anal.calcd for C12H11N5O2S: C, 49.82; H, 3.83; N, 24.21. Found: C, 49.63; H, 3.85; N, 24.22.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-phenyl-ethylimino]-2,3-dihydro-indol-2-one (
4h
). m.p. 140°C; IR (KBr): 3265, 3175, 2986, 1705, 1620, 1580, 1465, 670 cm−1; 1H NMR (DMSO-d6): 3.33 (d, 2H, CH2), 4.80 (t, 1H, CH), 7.12–7.26 (m, 5H, aromatic), 7.03–7.67 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 42.8, 56.4, 120, 122, 124.2, 128.8, 132, 138, 146.2, 162.8, 176.2, 178. Anal.calcd for C18H15N5OS: C, 61.87; H, 4.33; N, 20.04. Found: C, 61.68; H, 4.35; N, 20.06.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-phenylethylimino]-5-chloro-2,3-dihydro-indol-2-one (
4i
). m.p. 140°C; IR (KBr): 3263, 3177, 2980, 1706, 1619, 1580, 1462, 695, 670 cm−1; 1H NMR (DMSO-d6): 3.33 (d, 2H, CH2), 4.80 (t, 1H, CH), 7.12–7.26 (m, 5H, aromatic), 7.28–7.61 (m, 3H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 42, 56, 120.2, 122.4, 124, 128, 132, 144, 162, 176, 178.8. Anal.calcd for C18H14ClN5OS: C, 56.32; H, 3.68; N, 18.24. Found: C, 56.51; H, 3.66; N, 18.25.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-(1H-imidazol-4-yl)-ethylimino]-5-chloro-2,3-dihydro-indol-2-one (
4j
). m.p. 202°C; IR (KBr): 3265, 3170, 2985, 1705, 1619, 1580, 1462, 698, 670 cm−1; 1H NMR (DMSO-d6): 3.33 (d, 2H, CH2), 4.80 (t, 1H, CH), 6.80 (d, 1H, CH), 8.73 (d, 1H, CH), 7.28–7.61 (m, 3H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H), 13.4 (dd, 1H, NH) ppm. 13C-NMR (400 MHz, DMSO): 38, 56.8, 120, 122.2, 124, 128.6, 132, 136, 162.2, 176.4, 178. Anal.calcd for C15H12ClN7OS: C, 48.19; H, 3.24; N, 26.23. Found: C, 48.38; H, 3.26; N, 26.24.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-3-methylsulfanyl-propylimino]-5-chloro-2,3-dihydro-indol-2-one (
4k
). m.p. 190°C; IR (KBr): 3263, 3177, 2980, 1706, 1620, 1580, 1465, 690, 673 cm−1; 1H NMR (DMSO-d6): 2.09 (s, 3H, CH3), 2.31 (q, 2H, CH2), 2.44 (t, 2H, CH2), 4.41 (t, 1H, CH), 7.28–7.61 (m, 3H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 18, 30.4, 38, 54.4, 120.2, 122.8, 124.4, 128, 132, 144, 162, 176 and 178. Anal.calcd for C14H14ClN5OS2: C, 45.71; H, 3.84; N, 19.04. Found: C, 45.52; H, 3.86; N, 19.05.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-(1H-indol-3-yl)-ethylimino]-5-chloro-2,3-dihydro-indol-2-one (
4l
). m.p. 180°C; IR (KBr): 3265, 3175, 2986, 1705, 1619, 1580, 1462, 695, 670 cm−1; 1H NMR (DMSO-d6): 3.20 (d, 2H, CH2), 4.80 (t, 1H, CH), 7.18 (s 1H, CH), 10.85 (s, 1H, NH), 7.28–7.61 (m, 3H, aromatic), 6.97–7.58 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 36, 58.4, 110, 112, 120, 122, 124, 128.2, 132, 136, 144.4, 162.8, 176.2, 178.2. Anal.calcd for C20H15ClN6OS: C, 56.80; H, 3.58; N, 19.87. Found: C, 56.61; H, 3.55; N, 19.89.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-phenyl-ethylimino]-5-nitro-2,3-dihydro-indol-2-one (
4m
). m.p. 210°C; IR (KBr): 3263, 3177, 2980, 1706, 1615, 1580, 1462, 1362, 670 cm−1; 1H NMR (DMSO-d6): 3.33 (d, 2H, CH2), 4.80 (t, 1H, CH), 7.12–7.26 (m, 5H, aromatic), 7.93–8.53 (m, 3H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 42, 56.4, 120, 122, 124, 128, 132, 144, 152, 162, 176, 178. Anal.calcd for C18H14N6O3S: C, 54.81; H, 3.58; N, 21.31. Found: C, 54.62; H, 3.56; N, 21.34.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-(1H-imidazol-4-yl)-ethylimino]-5-nitro-2,3-dihydro-indol-2-one (
4n
). m.p. 203°C; IR (KBr): 3265, 3175, 2986, 1705, 1619, 1585, 1460, 1365, 672 cm−1; 1H NMR (DMSO-d6): 3.33 (d, 2H, CH2), 4.80 (t, 1H, CH), 6.80 (d, 1H, CH), 8.73 (d, 1H, CH), 7.93–8.53 (m, 3H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H), 13.4 (dd, 1H, NH) ppm. 13C-NMR (400 MHz, DMSO): 37, 56, 118, 120.2, 122.8, 124.6, 128.2, 132.2, 144.4, 152.2, 162.8, 176.2, 178.4. Anal.calcd for C15H12N8O3S: C, 46.87; H, 3.15; N, 29.15. Found: C, 46.68; H, 3.17; N, 29.17.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-3-methylsulfanyl-propylimino]-5-nitro-2,3-dihydro-indol-2-one (
4o
). m.p. 130°C; IR (KBr): 3260, 3170, 2985, 1702, 1615, 1580, 1462, 1362, 670 cm−1; 1H NMR (DMSO-d6): 2.09 (s, 3H,CH3), 2.31 (q, 2H, CH2), 2.44 (t, 2H, CH2), 4.41 (t, 1H, CH), 7.93–8.53 (m, 3H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 18, 30, 38, 54, 122.2, 124.8, 128.4, 134.2, 144.8, 152.6, 162.2, 176.4, 178.2. Anal.calcd for C14H14N6O3S2: C, 44.43; H, 3.73; N, 22.21. Found: C, 44.62; H, 3.71; N, 22.23.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-(1H-indol-3-yl)-ethylimino]-5-nitro-2,3-dihydro-indol-2-one (
4p
). m.p. 212°C; IR (KBr): 3263, 3177, 2980, 1706, 1620, 1585, 1460, 1362, 675 cm−1; 1H NMR (DMSO-d6): 3.20 (d, 2H, CH2), 4.80 (t, 1H, CH), 7.18 (s 1H, CH), 10.85 (s, 1H, NH), 7.93–8.53 (m, 3H, aromatic), 6.97–7.58 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 36, 58.4, 110, 118, 120.2, 122, 124, 128, 132, 144, 152, 162, 176.8, 178. Anal.calcd for C20H15N7O3S: C, 55.42; H, 3.49; N, 22.62. Found: C, 55.23; H, 3.47; N, 22.63.


## 3.1. General

Reagents and solvents were obtained from commercial sources and used without further purification. Melting points were determined on a Toshniwal apparatus. The spectral analyses of synthesized compounds have been carried out at SAIF, Punjab University, Chandigarh. Purity of all compounds was checked by TLC using “G” coated glass plates and n-hexane : ethyl acetate (7 : 3) as eluent. IR spectra were recorded in KBr on a Perkin Elmer Infrared RXI FTIR spectrophotometer and1HNMR spectra were recorded on Bruker Avance II 400 NMR spectrometer using DMSO-d6 and CDCl3 as solvent and tetramethylsilane (TMS) as internal reference standard. The obtained products were identified from their spectral (1HNMR, 13C NMR, and IR) studies.


## 3.2. General Procedure for Extraction of Lemon Juice

Fresh lemon was cut by using knife and then pieces were pressed manually using domestic presser to extract juice. Then juice was then filtered through cotton/muslin cloth and then through filter paper to remove solid material and to get clear juice which was used as a catalyst.


## 3.3. Green Route for the Synthesis of 3-[1-(5-Amino-[1,3,4]-thiadiazol-2-yl)-substitutedethylimino]-5-substituted-2,3-dihydro-indol-2-ones (4a–p)

An equimolar mixture of substituted 1H-indole-2,3-diones (0.012 mol), amino acids (0.012 mol), and thiosemicarbazide in water (15 mL containing 1 mL of ethanol) in the presence of lemon juice (2 mL) was mixed in round bottom flask and the mixture was refluxed for the time needed to complete the reaction (as monitored by TLC). The initial syrupy reaction mixture solidifies within 2-3 hrs. After completion of reaction, mixture was cooled to room temperature and the solid mass obtained was filtered, washed with water, and dried. The desired products were obtained with satisfactory yields without any further purification.The spectroscopic characterization data of (4a–p) are given below.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-ethylimino]-2,3-dihydro-indol-2-one (
4a
). m.p. 195°C; IR (KBr): 3259, 3157, 2923, 1706, 1619, 1585, 1462, 673 cm−1; 1H NMR (DMSO-d6): 1.56 (d, 3H, CH3), 4.59 (q, 1H, CH), 7.03–7.67 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 23.8, 51.4, 120, 122, 124, 128, 132, 146.4, 162, 176, 178. Anal.calcd for C12H11N5OS: C, 52.73; H, 4.06; N, 25.62. Found: C, 52.91; H, 4.09; N, 25.63.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-3-methylsulfanyl-propylimino]-2,3-dihydro-indol-2-one (
4b
). m.p. 170°C; IR (KBr): 3263, 3177, 2980, 1706, 1620, 1580, 1462, 670 cm−1; 1H NMR (DMSO-d6): 2.09 (s, 3H, CH3), 2.31 (q, 2H, CH2), 2.44 (t, 2H, CH2), 4.41 (t, 1H, CH), 7.03–7.67 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 17, 30.4, 38.2, 52.4, 122, 124, 126, 128, 132, 146.2, 160, 172, 174. Anal.calcd for C14H15N5OS2: C, 50.43; H, 4.53; N, 21.00. Found: C, 50.24; H, 4.56; N, 21.02.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-(1H-imidazol-4-yl)-ethylimino]-2,3-dihydro-indol-2-one (
4c
). m.p. 103°C; IR (KBr): 3260, 3175, 2986, 1705, 1619, 1585, 1462, 673 cm−1; 1H NMR (DMSO-d6): 3.33 (d, 2H, CH2), 4.80 (t, 1H, CH), 6.80 (d, 1H, CH), 8.73 (d, 1H, CH), 7.03–7.67 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H), 13.4 (dd, 1H, NH) ppm. 13C-NMR (400 MHz, DMSO): 36, 56, 118, 120, 122.6, 124.8, 128.2, 132.2, 134.2, 136.8, 146.8, 162.8, 174.2, 176. Anal.calcd for C15H13N7OS: C, 53.09; H, 3.86; N, 28.89. Found: C, 53.27; H, 3.89; N, 28.91.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-(1H-indol-3-yl)-ethylimino]-2,3-dihydro-indol-2-one (
4d
). m.p. 190°C; IR (KBr): 3263, 3177, 2980, 1706, 1619, 1580, 1462, 670 cm−1; 1H NMR (DMSO-d6): 3.20 (d, 2H, CH2), 4.80 (t, 1H, CH), 7.18 (s 1H, CH), 10.85 (s, 1H, NH), 7.03–7.67 (m, 4H, aromatic), 6.97–7.58 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 36.8, 58, 110, 112, 118, 120.2, 122.8, 124, 128, 130.2, 132.6, 136, 146, 164.4, 176, 178.2. Anal.calcd for C20H16N6OS: C, 61.84; H, 4.15; N, 21.63. Found: C, 61.66; H, 4.18; N, 21.65.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-methylbutylimino]-2,3-dihydro-indol-2-one (
4e
). m.p. 170°C; IR (KBr): 3263, 3086, 2986, 2876, 1733, 1621, 1594, 1462, 673 cm−1; 1H NMR (DMSO-d6): 0.96 (t, 3H, CH3), 1.29 (q, 2H, CH2), 1.06 (d, 3H, CH3), 2.00 (m, 1H, CH), 4.40 (d, 1H, CH), 7.03–7.67 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 11.6, 15.8, 24.8, 38, 58.2, 120.2, 122.2, 124.8, 128, 132, 142.2, 162.2, 176.2, 178. Anal.calcd for C15H17N5OS: C, 57.12; H, 5.43; N, 22.21. Found: C, 57.32; H, 5.45; N, 22.23.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-methylpropylimino]-2,3-dihydro-indol-2-one (
4f
). m.p. 190°C; IR (KBr): 3260, 3150, 2877, 2803, 1695, 1620, 1580, 1465, 670 cm−1; 1H NMR (DMSO-d6): 1.01 (d, 3H, CH3), 1.01 (d, 3H, CH3), 2.2 (m, 1H, CH), 4.40 (d, 1H, CH), 7.03–7.67 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 18.2, 36.2, 78.6, 110, 126, 128, 130, 142, 143, 162.8, 176, 178.2. Anal.calcd for C14H15N5OS: C, 55.80; H, 5.02; N, 23.24. Found: C, 55.62; H, 5.04; N, 23.25.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-hydroxyethylimino]-2,3-dihydro-indol-2-one (
4g
). m.p. 98°C; IR (KBr): 3465, 3263, 3177, 2980, 1706, 1619, 1580, 1462, 673 cm−1; 1H NMR (DMSO-d6): 4.30 (d, 2H, CH2), 4.50 (t, 1H, CH), 4.78 (s, 1H, OH), 7.03–7.67 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 51.4, 68, 120, 122, 124, 128, 132, 146.2, 162.8, 176.2, 178.8. Anal.calcd for C12H11N5O2S: C, 49.82; H, 3.83; N, 24.21. Found: C, 49.63; H, 3.85; N, 24.22.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-phenyl-ethylimino]-2,3-dihydro-indol-2-one (
4h
). m.p. 140°C; IR (KBr): 3265, 3175, 2986, 1705, 1620, 1580, 1465, 670 cm−1; 1H NMR (DMSO-d6): 3.33 (d, 2H, CH2), 4.80 (t, 1H, CH), 7.12–7.26 (m, 5H, aromatic), 7.03–7.67 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 42.8, 56.4, 120, 122, 124.2, 128.8, 132, 138, 146.2, 162.8, 176.2, 178. Anal.calcd for C18H15N5OS: C, 61.87; H, 4.33; N, 20.04. Found: C, 61.68; H, 4.35; N, 20.06.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-phenylethylimino]-5-chloro-2,3-dihydro-indol-2-one (
4i
). m.p. 140°C; IR (KBr): 3263, 3177, 2980, 1706, 1619, 1580, 1462, 695, 670 cm−1; 1H NMR (DMSO-d6): 3.33 (d, 2H, CH2), 4.80 (t, 1H, CH), 7.12–7.26 (m, 5H, aromatic), 7.28–7.61 (m, 3H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 42, 56, 120.2, 122.4, 124, 128, 132, 144, 162, 176, 178.8. Anal.calcd for C18H14ClN5OS: C, 56.32; H, 3.68; N, 18.24. Found: C, 56.51; H, 3.66; N, 18.25.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-(1H-imidazol-4-yl)-ethylimino]-5-chloro-2,3-dihydro-indol-2-one (
4j
). m.p. 202°C; IR (KBr): 3265, 3170, 2985, 1705, 1619, 1580, 1462, 698, 670 cm−1; 1H NMR (DMSO-d6): 3.33 (d, 2H, CH2), 4.80 (t, 1H, CH), 6.80 (d, 1H, CH), 8.73 (d, 1H, CH), 7.28–7.61 (m, 3H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H), 13.4 (dd, 1H, NH) ppm. 13C-NMR (400 MHz, DMSO): 38, 56.8, 120, 122.2, 124, 128.6, 132, 136, 162.2, 176.4, 178. Anal.calcd for C15H12ClN7OS: C, 48.19; H, 3.24; N, 26.23. Found: C, 48.38; H, 3.26; N, 26.24.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-3-methylsulfanyl-propylimino]-5-chloro-2,3-dihydro-indol-2-one (
4k
). m.p. 190°C; IR (KBr): 3263, 3177, 2980, 1706, 1620, 1580, 1465, 690, 673 cm−1; 1H NMR (DMSO-d6): 2.09 (s, 3H, CH3), 2.31 (q, 2H, CH2), 2.44 (t, 2H, CH2), 4.41 (t, 1H, CH), 7.28–7.61 (m, 3H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 18, 30.4, 38, 54.4, 120.2, 122.8, 124.4, 128, 132, 144, 162, 176 and 178. Anal.calcd for C14H14ClN5OS2: C, 45.71; H, 3.84; N, 19.04. Found: C, 45.52; H, 3.86; N, 19.05.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-(1H-indol-3-yl)-ethylimino]-5-chloro-2,3-dihydro-indol-2-one (
4l
). m.p. 180°C; IR (KBr): 3265, 3175, 2986, 1705, 1619, 1580, 1462, 695, 670 cm−1; 1H NMR (DMSO-d6): 3.20 (d, 2H, CH2), 4.80 (t, 1H, CH), 7.18 (s 1H, CH), 10.85 (s, 1H, NH), 7.28–7.61 (m, 3H, aromatic), 6.97–7.58 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 36, 58.4, 110, 112, 120, 122, 124, 128.2, 132, 136, 144.4, 162.8, 176.2, 178.2. Anal.calcd for C20H15ClN6OS: C, 56.80; H, 3.58; N, 19.87. Found: C, 56.61; H, 3.55; N, 19.89.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-phenyl-ethylimino]-5-nitro-2,3-dihydro-indol-2-one (
4m
). m.p. 210°C; IR (KBr): 3263, 3177, 2980, 1706, 1615, 1580, 1462, 1362, 670 cm−1; 1H NMR (DMSO-d6): 3.33 (d, 2H, CH2), 4.80 (t, 1H, CH), 7.12–7.26 (m, 5H, aromatic), 7.93–8.53 (m, 3H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 42, 56.4, 120, 122, 124, 128, 132, 144, 152, 162, 176, 178. Anal.calcd for C18H14N6O3S: C, 54.81; H, 3.58; N, 21.31. Found: C, 54.62; H, 3.56; N, 21.34.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-(1H-imidazol-4-yl)-ethylimino]-5-nitro-2,3-dihydro-indol-2-one (
4n
). m.p. 203°C; IR (KBr): 3265, 3175, 2986, 1705, 1619, 1585, 1460, 1365, 672 cm−1; 1H NMR (DMSO-d6): 3.33 (d, 2H, CH2), 4.80 (t, 1H, CH), 6.80 (d, 1H, CH), 8.73 (d, 1H, CH), 7.93–8.53 (m, 3H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H), 13.4 (dd, 1H, NH) ppm. 13C-NMR (400 MHz, DMSO): 37, 56, 118, 120.2, 122.8, 124.6, 128.2, 132.2, 144.4, 152.2, 162.8, 176.2, 178.4. Anal.calcd for C15H12N8O3S: C, 46.87; H, 3.15; N, 29.15. Found: C, 46.68; H, 3.17; N, 29.17.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-3-methylsulfanyl-propylimino]-5-nitro-2,3-dihydro-indol-2-one (
4o
). m.p. 130°C; IR (KBr): 3260, 3170, 2985, 1702, 1615, 1580, 1462, 1362, 670 cm−1; 1H NMR (DMSO-d6): 2.09 (s, 3H,CH3), 2.31 (q, 2H, CH2), 2.44 (t, 2H, CH2), 4.41 (t, 1H, CH), 7.93–8.53 (m, 3H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 18, 30, 38, 54, 122.2, 124.8, 128.4, 134.2, 144.8, 152.6, 162.2, 176.4, 178.2. Anal.calcd for C14H14N6O3S2: C, 44.43; H, 3.73; N, 22.21. Found: C, 44.62; H, 3.71; N, 22.23.3-[1-(5-Amino-[1,3,4]thiadiazol-2-yl)-2-(1H-indol-3-yl)-ethylimino]-5-nitro-2,3-dihydro-indol-2-one (
4p
). m.p. 212°C; IR (KBr): 3263, 3177, 2980, 1706, 1620, 1585, 1460, 1362, 675 cm−1; 1H NMR (DMSO-d6): 3.20 (d, 2H, CH2), 4.80 (t, 1H, CH), 7.18 (s 1H, CH), 10.85 (s, 1H, NH), 7.93–8.53 (m, 3H, aromatic), 6.97–7.58 (m, 4H, aromatic), 7.22 (s, 2H, NH2), 11.18 (s, 1H, N–H) ppm. 13C-NMR (400 MHz, DMSO): 36, 58.4, 110, 118, 120.2, 122, 124, 128, 132, 144, 152, 162, 176.8, 178. Anal.calcd for C20H15N7O3S: C, 55.42; H, 3.49; N, 22.62. Found: C, 55.23; H, 3.47; N, 22.63.


## 4. Antimicrobial Activity

### 4.1. Antibacterial Activity

All the synthesized compounds were tested for in vitro antibacterial activity by twofold serial dilution assay [46] against the reference compound streptomycin. The minimal inhibitory concentration (MIC) is shown in Tables 2 and 4. During MIC determination by twofold serial dilution method, compounds 4g, 4j, and 4m exhibit good activities against all bacterial strains at a MIC value of 1000 μg/mL. Admirable activities against M. luteus and E. coli are displayed by compounds 4d, 4e, 4g, 4h, 4i, 4j, 4l, and 4o at a MIC value of 500 μg/mL. Compounds, 4a, 4e, 4o, and 4p display higher activities against S. aureus, at a MIC value of 1000 μg/mL.Table 2
Antibacterial and antifungal evaluation of the synthesized compounds (4a–p).
Compound
MIC (ug/mL)
Bacterial strains
Fungal strains
Pseudomonas aeruginosa
Bacillus licheniformis
Staphylococcus aureus
Micrococcus luteus
Escherichia coli
Aspergillussp.
Penicilliumsp.
Alternaria brassicicola
Chaetomium orium
Lycopodiumsp.
4a
− −
− −
1000
1000
1000
− −
− −
− −
− −
1000
4b
− −
− −
− −
− −
− −
− −
− −
− −
− −
− −
4c
1000
1000
− −
− −
− −
>1000
− −
− −
− −
− −
4d
− −
− −
− −
500
500
− −
− −
− −
− −
− −
4e
− −
− −
1000
500
1000
− −
− −
− −
− −
− −
4f
− −
− −
− −
− −
− −
− −
− −
− −
− −
− −
4g
1000
1000
1000
500
500
1000
− −
− −
− −
− −
4h
− −
1000
− −
500
500
1000
− −
1000
1000
− −
4i
− −
1000
− −
500
500
− −
1000
1000
1000
− −
4j
1000
1000
1000
500
− −
− −
− −
− −
− −
− −
4k
− −
− −
− −
− −
1000
− −
1000
1000
1000
1000
4l
1000
− −
− −
500
− −
− −
− −
− −
− −
− −
4m
1000
1000
1000
500
1000
1000
1000
1000
1000
− −
4n
-
-
1000
− −
− −
1000
>1000
− −
− −
>1000
− −
4o
− −
− −
1000
500
− −
− −
− −
− −
− −
− −
4p
1000
1000
1000
− −
− −
− −
− −
− −
1000
1000
SolventDMSO
− −
− −
− −
− −
− −
− −
− −
− −
− −
− −


### 4.2. Antifungal Activity

The antifungal activity of the compounds was also studied withAspergillus sp., Penicillium sp., Alternaria brassicicola, Chaetomium orium, and Lycopodium sp. fungi. The results are summarized in Tables 2 and 3. It has been observed that all synthesized chemical compounds showed lesser antifungal activity as compared to antibacterial activity. On MIC determination, compounds 4h, 4i, 4k, and4m showed excellent antimicrobial activities at a MIC value of 1000 μg/mL. Modest activities are displayed by compound 4n against Aspergillus sp. andChaetomium orium at a MIC value of >1000 μg/mL, whereas compound 4a, 4c, and4g exhibit mild activities against Aspergillus sp. andLycopodium sp. at a MIC value of 1000 μg/mL.Table 3
Minimum inhibitory concentration for fungi.
Compound
MIC (ug/mL)
Aspergillussp.
Penicilliumsp.
Alternaria brassicicola
Chaetomium orium
Lycopodiumsp.
250
500
1000
250
500
1000
250
500
1000
250
500
1000
250
500
1000
4a
+
+
+
+
+
+
+
+
+
+
+
+
+
−
− −
*
4b
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4c
+
+
− −
*
+
+
+
+
+
+
+
+
+
+
+
+
4d
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4e
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4f
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4g
+
+
−
+
+
+
+
+
+
+
+
+
−
+
+
4h
+
+
− −
*
+
+
+
+
+
− −
*
+
+
− −
*
+
+
+
4i
+
+
+
+
+
− −
*
+
+
− −
*
+
+
− −
*
+
+
+
4j
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4k
+
+
+
+
+
− −
*
+
+
− −
*
+
+
− −
*
+
+
− −
*
4l
+
+
− −
*
+
+
+
+
+
+
+
+
−
+
+
+
4m
+
+
− −
*
+
+
− −
*
+
+
−
+
+
− −
*
+
+
−
4n
+
+
− −
*
+
+
+
+
+
−
+
+
− −
*
+
+
−
4o
+
+
+
+
+
+
+
+
−
+
+
+
+
+
−
4p
+
+
+
+
+
+
+
+
−
+
+
− −
*
+
+
− −
*
SolventDMSO
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
Itraconazole
-
-
-
-
− − −
-
-
-
-
− − −
− − −
*Moderately active (zone of inhibition 8–10 mm).Table 4
Minimum inhibitory concentration for bacteria.
Compound
MIC (ug/mL)
Pseudomonas aeruginosa
Bacillus licheniformis
Staphylococcus aureus
Micrococcus luteus
Escherichia coli
250
500
1000
250
500
1000
250
500
1000
250
500
1000
250
500
1000
4a
+
+
+
+
+
+
+
−
− −
*
+
−
− −
*
+
−
− −
*
4b
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4c
+
−
− −
*
+
−
− −
*
+
+
+
+
+
+
+
−
− −
*
4d
+
+
+
+
+
+
+
+
+
+
− −
*
− −
*
+
− −
*
− −
*
4e
+
+
+
+
+
+
+
−
− −
*
+
− −
*
− −
*
+
−
− −
*
4f
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4g
+
−
− −
*
+
−
− −
*
+
−
− −
*
+
− −
*
− −
*
−
− −
*
− −
*
4h
+
+
+
+
−
− −
*
+
+
+
−
− −
*
− −
*
+
− −
*
− −
*
4i
+
+
+
+
−
− −
*
+
+
+
−
− −
*
− −
*
−
− −
*
− −
*
4j
+
−
− −
*
+
+
− −
*
+
+
− −
*
−
− −
*
− −
*
+
− −
*
− −
*
4k
+
+
+
+
+
+
+
+
+
+
+
+
+
−
− −
*
4l
+
+
− −
*
+
+
+
+
+
+
+
− −
*
− −
*
+
+
+
4m
+
−
− −
*
+
+
− −
*
+
−
− −
+
+
+
+
−
− −
*
4n
+
+
−
+
+
− −
*
+
+
+
+
− −
*
− −
*
+
+
+
4o
+
+
−
+
+
+
+
−
− −
*
+
− −
*
− −
*
+
+
− −
*
4p
+
−
− −
*
+
+
− −
*
+
−
− −
*
+
+
+
+
+
+
SolventDMSO
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
Streptomycin
− − − −
+
+
+
− − − −
Gentamycin
− − −
− − −
− − − −
− − − −
− − − −
+: inactive (zone of inhibition < 6 mm); −: slightly active (zone of inhibition 6–8 mm); − −: moderately active (zone of inhibition 8–10 mm); − − − −: highly active (zone of inhibition > 10 mm); filled part showing MIC for particular organism.Determination of Minimal Inhibitory Concentrations (MIC). Minimum inhibitory concentration was determined by twofold serial dilution method [46]. A series of test tubes were prepared containing the same volume of media inoculated with the test organism. Drug was added to the tubes in a stepwise dilution by a factor of 2 (twofold serial dilution); that is, the concentration of drug in the first tube is 1000 μg/mL, in the second tube it will be 500 μg/mL, and in the third it will be 250 μg/mL. Cultures were incubated at 24 hrs for bacteria at 37°C and 48 hrs for fungi at 30°C. One tube was left without drug only solvent to serve as a positive control for the growth of the organism. After incubation, tubes were examined for microbial growth and the minimum inhibitory concentrations (the minimum concentration of each treatment that inhibits microbial growth after the incubation period) were measured. Tubes are inspected visually to determine the growth of the organism indicated by turbidity and simultaneously streak on Petri dish containing nutrient agar medium; after incubation (24 hours for bacteria and 48 hrs for fungal strains) microbial growth were measured.From the screening results, it is observed that the presence of electron withdrawing groups like Cl and NO2 group at 5th position of indole ring exhibits significant activity in comparison to unsubstituted compounds. However other synthesized compounds of the series also exhibit moderate to significant activity against the microorganisms as mentioned above.


### 4.3. Evaluation of Cytotoxic Effects

The uncontrolled growth of cells in the body, started due to certain stimuli, lays the foundation of cancer. Anticancer drugs either kill cancer cells or modify their growth. Among the heterocyclic compounds, five membered heterocyclic moieties fused with aromatic ring system with various heteroatoms like N, S, and O are potential anticancer agents [47]. Synthesis of nitrogen containing heterocyclic compounds has been a subject of great interest due to the wide application in agrochemical and pharmaceutical fields. Heterocycles like indole, pyrimidine, pyridine, quinoline, and so forth are an integral part of a huge number of natural and synthetic compounds and play important roles in the biological systems. For developing the suitable leads for anticancer drugs, introduction of appropriate substituents at C-3 of indole is required [48]. It has also been observed that Schiff bases also play a major role in developing cytotoxic drugs [49, 50]. Hence, an attempt has been made to synthesize Schiff bases incorporating indole moiety and the synthesized compounds 4a, 4e, 4f, and 4h were evaluated [51] for their cytotoxic effects against Human colon cancer cell line Colo205. Percent growth was calculated on a plate-by-plate basis for test wells relative to control wells.Percent growth was expressed as the ratio of average absorbance of the test well to the average absorbance of the control wells* 100.Using the six-absorbance measurements [time zero (Tz), control growth (C), and test growth in the presence of drug at the four concentration levels (Ti)], the percentage growth was calculated at each of the drug concentration levels.Percentage growth inhibition was calculated as[(Ti − Tz)/(C − Tz)] × 100 for concentrations for which Ti  ≥ Tz (Ti − Tz) positive or zero,
[(Ti − Tz)/Tz] × 100 for concentrations for which Ti < Tz. (Ti − Tz) negative.The dose response parameters were calculated for each test article. Growth inhibition of 50% (GI50) was calculated from [(Ti − Tz)/(C − Tz)] × 100 = 50, which is the drug concentration resulting in a 50% reduction in the net protein increase (as measured by SRB staining) in control cells during the drug incubation. The drug concentration resulting in total growth inhibition (TGI) was calculated from Ti = Tz. The LC50 (concentration of drug resulting in a 50% reduction in the measured protein at the end of the drug treatment as compared to that at the beginning) indicating a net loss of cells following treatment is calculated from(1)
[
(
Ti
-
Tz
)
Tz
]
×
100
=
-
50
.Values were calculated for each of these three parameters if the level of activity was reached; however, if the effect was not reached or was exceeded, the values for that parameter were expressed as greater or less than the maximum or minimum concentration tested. The data of anticancer activity in terms of % control growth at different molar drug concentrations are shown in Table4. Unfortunately, the evaluated compounds were not found to be active against human colon cancer cell line. Growth curve is presented in Figure 1.Figure 1
In vitro cytotoxic effects of amino acid Schiff bases against human colon cancer cell line Colo205.


#### 4.3.1. Definitions and Notes

GI50: growth inhibition of 50% (GI50) is calculated from [(Ti − Tz)/(C − Tz)] × 100 = 50, drug concentration resulting in a 50% reduction in the net protein increase;
TGI: drug concentration resulting in total growth inhibition (TGI) will be calculated from Ti = Tz;
LC50: concentration of drug resulting in a 50% reduction in the measured protein at the end of the drug treatment (as compared to that at the beginning) indicating a net loss of 50% cells following treatment is calculated from [(Ti − Tz)/Tz] × 100 = −50;
ADR: Adriamycin (doxorubicin) is positive control compound;GI50 value of ≤10−6 (i.e., 1 µmole) or ≤10 µg/mL is considered to demonstrate activity in case of pure compounds.For extracts, GI50 value ≤20µg/mL is considered to demonstrate activity.The bold highlighted test values under GI50 column indicate activity (see Table5).Table 5
In vitro cytotoxic effects of amino acid Schiff bases against human colon cancer cell line Colo205.
(a)
Entry
Human colon cancer cell line Colo205
% control growth
Molar drug concentration
Experiment 1
Experiment 2
Experiment 3
Average values
10−6 M
10−5 M
10−4 M
10−3 M
10−7 M
10−6 M
10−5 M
10−4 M
10−7 M
10−6 M
10−5 M
10−4 M
10−7 M
10−6 M
10−5 M
10−4 M
4a
98.3
91.4
91.2
29.4
96.3
93.2
91.8
28.9
90.4
94.9
83.6
22.9
95.0
93.2
88.9
27.0
4e
100.0
100.0
100.0
23.0
100.0
100.0
100.0
23.7
100.0
100.0
100.0
23.8
100.0
100.0
100.0
23.5
4f
100.0
98.0
96.3
39.7
100.0
96.3
95.1
38.2
100.0
100.0
100.0
43.4
100.0
98.1
97.1
40.4
4h
100.0
100.0
93.1
−25.0
100.0
99.4
91.5
−20.5
100.0
97.9
88.1
−28.3
100.0
99.1
90.9
−24.6
ADR
73.4
21.7
−64.1
−74.7
71.1
23.3
−70.2
−73.5
67.5
14.1
−66.1
−76.3
70.7
19.7
−66.8
−74.8
(b)
Human colon cancer cell line Colo205
Molar drug concentration calculated from graph
Colo205
LC50
TGI
GI50
4a
>100
>100
67.2
4e
>100
>100
68.0
4f
>100
>100
85.4
4h
>100
81.6
41.8
ADR
67.7
15.3
<10


## 4.1. Antibacterial Activity

All the synthesized compounds were tested for in vitro antibacterial activity by twofold serial dilution assay [46] against the reference compound streptomycin. The minimal inhibitory concentration (MIC) is shown in Tables 2 and 4. During MIC determination by twofold serial dilution method, compounds 4g, 4j, and 4m exhibit good activities against all bacterial strains at a MIC value of 1000 μg/mL. Admirable activities against M. luteus and E. coli are displayed by compounds 4d, 4e, 4g, 4h, 4i, 4j, 4l, and 4o at a MIC value of 500 μg/mL. Compounds, 4a, 4e, 4o, and 4p display higher activities against S. aureus, at a MIC value of 1000 μg/mL.Table 2
Antibacterial and antifungal evaluation of the synthesized compounds (4a–p).
Compound
MIC (ug/mL)
Bacterial strains
Fungal strains
Pseudomonas aeruginosa
Bacillus licheniformis
Staphylococcus aureus
Micrococcus luteus
Escherichia coli
Aspergillussp.
Penicilliumsp.
Alternaria brassicicola
Chaetomium orium
Lycopodiumsp.
4a
− −
− −
1000
1000
1000
− −
− −
− −
− −
1000
4b
− −
− −
− −
− −
− −
− −
− −
− −
− −
− −
4c
1000
1000
− −
− −
− −
>1000
− −
− −
− −
− −
4d
− −
− −
− −
500
500
− −
− −
− −
− −
− −
4e
− −
− −
1000
500
1000
− −
− −
− −
− −
− −
4f
− −
− −
− −
− −
− −
− −
− −
− −
− −
− −
4g
1000
1000
1000
500
500
1000
− −
− −
− −
− −
4h
− −
1000
− −
500
500
1000
− −
1000
1000
− −
4i
− −
1000
− −
500
500
− −
1000
1000
1000
− −
4j
1000
1000
1000
500
− −
− −
− −
− −
− −
− −
4k
− −
− −
− −
− −
1000
− −
1000
1000
1000
1000
4l
1000
− −
− −
500
− −
− −
− −
− −
− −
− −
4m
1000
1000
1000
500
1000
1000
1000
1000
1000
− −
4n
-
-
1000
− −
− −
1000
>1000
− −
− −
>1000
− −
4o
− −
− −
1000
500
− −
− −
− −
− −
− −
− −
4p
1000
1000
1000
− −
− −
− −
− −
− −
1000
1000
SolventDMSO
− −
− −
− −
− −
− −
− −
− −
− −
− −
− −


## 4.2. Antifungal Activity

The antifungal activity of the compounds was also studied withAspergillus sp., Penicillium sp., Alternaria brassicicola, Chaetomium orium, and Lycopodium sp. fungi. The results are summarized in Tables 2 and 3. It has been observed that all synthesized chemical compounds showed lesser antifungal activity as compared to antibacterial activity. On MIC determination, compounds 4h, 4i, 4k, and4m showed excellent antimicrobial activities at a MIC value of 1000 μg/mL. Modest activities are displayed by compound 4n against Aspergillus sp. andChaetomium orium at a MIC value of >1000 μg/mL, whereas compound 4a, 4c, and4g exhibit mild activities against Aspergillus sp. andLycopodium sp. at a MIC value of 1000 μg/mL.Table 3
Minimum inhibitory concentration for fungi.
Compound
MIC (ug/mL)
Aspergillussp.
Penicilliumsp.
Alternaria brassicicola
Chaetomium orium
Lycopodiumsp.
250
500
1000
250
500
1000
250
500
1000
250
500
1000
250
500
1000
4a
+
+
+
+
+
+
+
+
+
+
+
+
+
−
− −
*
4b
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4c
+
+
− −
*
+
+
+
+
+
+
+
+
+
+
+
+
4d
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4e
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4f
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4g
+
+
−
+
+
+
+
+
+
+
+
+
−
+
+
4h
+
+
− −
*
+
+
+
+
+
− −
*
+
+
− −
*
+
+
+
4i
+
+
+
+
+
− −
*
+
+
− −
*
+
+
− −
*
+
+
+
4j
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4k
+
+
+
+
+
− −
*
+
+
− −
*
+
+
− −
*
+
+
− −
*
4l
+
+
− −
*
+
+
+
+
+
+
+
+
−
+
+
+
4m
+
+
− −
*
+
+
− −
*
+
+
−
+
+
− −
*
+
+
−
4n
+
+
− −
*
+
+
+
+
+
−
+
+
− −
*
+
+
−
4o
+
+
+
+
+
+
+
+
−
+
+
+
+
+
−
4p
+
+
+
+
+
+
+
+
−
+
+
− −
*
+
+
− −
*
SolventDMSO
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
Itraconazole
-
-
-
-
− − −
-
-
-
-
− − −
− − −
*Moderately active (zone of inhibition 8–10 mm).Table 4
Minimum inhibitory concentration for bacteria.
Compound
MIC (ug/mL)
Pseudomonas aeruginosa
Bacillus licheniformis
Staphylococcus aureus
Micrococcus luteus
Escherichia coli
250
500
1000
250
500
1000
250
500
1000
250
500
1000
250
500
1000
4a
+
+
+
+
+
+
+
−
− −
*
+
−
− −
*
+
−
− −
*
4b
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4c
+
−
− −
*
+
−
− −
*
+
+
+
+
+
+
+
−
− −
*
4d
+
+
+
+
+
+
+
+
+
+
− −
*
− −
*
+
− −
*
− −
*
4e
+
+
+
+
+
+
+
−
− −
*
+
− −
*
− −
*
+
−
− −
*
4f
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
4g
+
−
− −
*
+
−
− −
*
+
−
− −
*
+
− −
*
− −
*
−
− −
*
− −
*
4h
+
+
+
+
−
− −
*
+
+
+
−
− −
*
− −
*
+
− −
*
− −
*
4i
+
+
+
+
−
− −
*
+
+
+
−
− −
*
− −
*
−
− −
*
− −
*
4j
+
−
− −
*
+
+
− −
*
+
+
− −
*
−
− −
*
− −
*
+
− −
*
− −
*
4k
+
+
+
+
+
+
+
+
+
+
+
+
+
−
− −
*
4l
+
+
− −
*
+
+
+
+
+
+
+
− −
*
− −
*
+
+
+
4m
+
−
− −
*
+
+
− −
*
+
−
− −
+
+
+
+
−
− −
*
4n
+
+
−
+
+
− −
*
+
+
+
+
− −
*
− −
*
+
+
+
4o
+
+
−
+
+
+
+
−
− −
*
+
− −
*
− −
*
+
+
− −
*
4p
+
−
− −
*
+
+
− −
*
+
−
− −
*
+
+
+
+
+
+
SolventDMSO
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
Streptomycin
− − − −
+
+
+
− − − −
Gentamycin
− − −
− − −
− − − −
− − − −
− − − −
+: inactive (zone of inhibition < 6 mm); −: slightly active (zone of inhibition 6–8 mm); − −: moderately active (zone of inhibition 8–10 mm); − − − −: highly active (zone of inhibition > 10 mm); filled part showing MIC for particular organism.Determination of Minimal Inhibitory Concentrations (MIC). Minimum inhibitory concentration was determined by twofold serial dilution method [46]. A series of test tubes were prepared containing the same volume of media inoculated with the test organism. Drug was added to the tubes in a stepwise dilution by a factor of 2 (twofold serial dilution); that is, the concentration of drug in the first tube is 1000 μg/mL, in the second tube it will be 500 μg/mL, and in the third it will be 250 μg/mL. Cultures were incubated at 24 hrs for bacteria at 37°C and 48 hrs for fungi at 30°C. One tube was left without drug only solvent to serve as a positive control for the growth of the organism. After incubation, tubes were examined for microbial growth and the minimum inhibitory concentrations (the minimum concentration of each treatment that inhibits microbial growth after the incubation period) were measured. Tubes are inspected visually to determine the growth of the organism indicated by turbidity and simultaneously streak on Petri dish containing nutrient agar medium; after incubation (24 hours for bacteria and 48 hrs for fungal strains) microbial growth were measured.From the screening results, it is observed that the presence of electron withdrawing groups like Cl and NO2 group at 5th position of indole ring exhibits significant activity in comparison to unsubstituted compounds. However other synthesized compounds of the series also exhibit moderate to significant activity against the microorganisms as mentioned above.


## 4.3. Evaluation of Cytotoxic Effects

The uncontrolled growth of cells in the body, started due to certain stimuli, lays the foundation of cancer. Anticancer drugs either kill cancer cells or modify their growth. Among the heterocyclic compounds, five membered heterocyclic moieties fused with aromatic ring system with various heteroatoms like N, S, and O are potential anticancer agents [47]. Synthesis of nitrogen containing heterocyclic compounds has been a subject of great interest due to the wide application in agrochemical and pharmaceutical fields. Heterocycles like indole, pyrimidine, pyridine, quinoline, and so forth are an integral part of a huge number of natural and synthetic compounds and play important roles in the biological systems. For developing the suitable leads for anticancer drugs, introduction of appropriate substituents at C-3 of indole is required [48]. It has also been observed that Schiff bases also play a major role in developing cytotoxic drugs [49, 50]. Hence, an attempt has been made to synthesize Schiff bases incorporating indole moiety and the synthesized compounds 4a, 4e, 4f, and 4h were evaluated [51] for their cytotoxic effects against Human colon cancer cell line Colo205. Percent growth was calculated on a plate-by-plate basis for test wells relative to control wells.Percent growth was expressed as the ratio of average absorbance of the test well to the average absorbance of the control wells* 100.Using the six-absorbance measurements [time zero (Tz), control growth (C), and test growth in the presence of drug at the four concentration levels (Ti)], the percentage growth was calculated at each of the drug concentration levels.Percentage growth inhibition was calculated as[(Ti − Tz)/(C − Tz)] × 100 for concentrations for which Ti  ≥ Tz (Ti − Tz) positive or zero,
[(Ti − Tz)/Tz] × 100 for concentrations for which Ti < Tz. (Ti − Tz) negative.The dose response parameters were calculated for each test article. Growth inhibition of 50% (GI50) was calculated from [(Ti − Tz)/(C − Tz)] × 100 = 50, which is the drug concentration resulting in a 50% reduction in the net protein increase (as measured by SRB staining) in control cells during the drug incubation. The drug concentration resulting in total growth inhibition (TGI) was calculated from Ti = Tz. The LC50 (concentration of drug resulting in a 50% reduction in the measured protein at the end of the drug treatment as compared to that at the beginning) indicating a net loss of cells following treatment is calculated from(1)
[
(
Ti
-
Tz
)
Tz
]
×
100
=
-
50
.Values were calculated for each of these three parameters if the level of activity was reached; however, if the effect was not reached or was exceeded, the values for that parameter were expressed as greater or less than the maximum or minimum concentration tested. The data of anticancer activity in terms of % control growth at different molar drug concentrations are shown in Table4. Unfortunately, the evaluated compounds were not found to be active against human colon cancer cell line. Growth curve is presented in Figure 1.Figure 1
In vitro cytotoxic effects of amino acid Schiff bases against human colon cancer cell line Colo205.


### 4.3.1. Definitions and Notes

GI50: growth inhibition of 50% (GI50) is calculated from [(Ti − Tz)/(C − Tz)] × 100 = 50, drug concentration resulting in a 50% reduction in the net protein increase;
TGI: drug concentration resulting in total growth inhibition (TGI) will be calculated from Ti = Tz;
LC50: concentration of drug resulting in a 50% reduction in the measured protein at the end of the drug treatment (as compared to that at the beginning) indicating a net loss of 50% cells following treatment is calculated from [(Ti − Tz)/Tz] × 100 = −50;
ADR: Adriamycin (doxorubicin) is positive control compound;GI50 value of ≤10−6 (i.e., 1 µmole) or ≤10 µg/mL is considered to demonstrate activity in case of pure compounds.For extracts, GI50 value ≤20µg/mL is considered to demonstrate activity.The bold highlighted test values under GI50 column indicate activity (see Table5).Table 5
In vitro cytotoxic effects of amino acid Schiff bases against human colon cancer cell line Colo205.
(a)
Entry
Human colon cancer cell line Colo205
% control growth
Molar drug concentration
Experiment 1
Experiment 2
Experiment 3
Average values
10−6 M
10−5 M
10−4 M
10−3 M
10−7 M
10−6 M
10−5 M
10−4 M
10−7 M
10−6 M
10−5 M
10−4 M
10−7 M
10−6 M
10−5 M
10−4 M
4a
98.3
91.4
91.2
29.4
96.3
93.2
91.8
28.9
90.4
94.9
83.6
22.9
95.0
93.2
88.9
27.0
4e
100.0
100.0
100.0
23.0
100.0
100.0
100.0
23.7
100.0
100.0
100.0
23.8
100.0
100.0
100.0
23.5
4f
100.0
98.0
96.3
39.7
100.0
96.3
95.1
38.2
100.0
100.0
100.0
43.4
100.0
98.1
97.1
40.4
4h
100.0
100.0
93.1
−25.0
100.0
99.4
91.5
−20.5
100.0
97.9
88.1
−28.3
100.0
99.1
90.9
−24.6
ADR
73.4
21.7
−64.1
−74.7
71.1
23.3
−70.2
−73.5
67.5
14.1
−66.1
−76.3
70.7
19.7
−66.8
−74.8
(b)
Human colon cancer cell line Colo205
Molar drug concentration calculated from graph
Colo205
LC50
TGI
GI50
4a
>100
>100
67.2
4e
>100
>100
68.0
4f
>100
>100
85.4
4h
>100
81.6
41.8
ADR
67.7
15.3
<10


## 4.3.1. Definitions and Notes

GI50: growth inhibition of 50% (GI50) is calculated from [(Ti − Tz)/(C − Tz)] × 100 = 50, drug concentration resulting in a 50% reduction in the net protein increase;
TGI: drug concentration resulting in total growth inhibition (TGI) will be calculated from Ti = Tz;
LC50: concentration of drug resulting in a 50% reduction in the measured protein at the end of the drug treatment (as compared to that at the beginning) indicating a net loss of 50% cells following treatment is calculated from [(Ti − Tz)/Tz] × 100 = −50;
ADR: Adriamycin (doxorubicin) is positive control compound;GI50 value of ≤10−6 (i.e., 1 µmole) or ≤10 µg/mL is considered to demonstrate activity in case of pure compounds.For extracts, GI50 value ≤20µg/mL is considered to demonstrate activity.The bold highlighted test values under GI50 column indicate activity (see Table5).Table 5
In vitro cytotoxic effects of amino acid Schiff bases against human colon cancer cell line Colo205.
(a)
Entry
Human colon cancer cell line Colo205
% control growth
Molar drug concentration
Experiment 1
Experiment 2
Experiment 3
Average values
10−6 M
10−5 M
10−4 M
10−3 M
10−7 M
10−6 M
10−5 M
10−4 M
10−7 M
10−6 M
10−5 M
10−4 M
10−7 M
10−6 M
10−5 M
10−4 M
4a
98.3
91.4
91.2
29.4
96.3
93.2
91.8
28.9
90.4
94.9
83.6
22.9
95.0
93.2
88.9
27.0
4e
100.0
100.0
100.0
23.0
100.0
100.0
100.0
23.7
100.0
100.0
100.0
23.8
100.0
100.0
100.0
23.5
4f
100.0
98.0
96.3
39.7
100.0
96.3
95.1
38.2
100.0
100.0
100.0
43.4
100.0
98.1
97.1
40.4
4h
100.0
100.0
93.1
−25.0
100.0
99.4
91.5
−20.5
100.0
97.9
88.1
−28.3
100.0
99.1
90.9
−24.6
ADR
73.4
21.7
−64.1
−74.7
71.1
23.3
−70.2
−73.5
67.5
14.1
−66.1
−76.3
70.7
19.7
−66.8
−74.8
(b)
Human colon cancer cell line Colo205
Molar drug concentration calculated from graph
Colo205
LC50
TGI
GI50
4a
>100
>100
67.2
4e
>100
>100
68.0
4f
>100
>100
85.4
4h
>100
81.6
41.8
ADR
67.7
15.3
<10


## 5. Conclusions

We have developed a convenient, simple, efficient, and eco-friendly green procedure for the synthesis of Schiff bases from 1H-indole-2,3-diones, various amino acids, and thiosemicarbazide under mild reaction conditions in an aqueous medium. Some of the major advantages of this protocol are the ambient conditions, good to excellent yields, simple work-up procedure, and use of water as a desirable solvent for chemical reaction for reasons cost, safety, and environmental concerns. Further, use of lemon juice as green catalyst makes this methodology an alternative platform to organic solvent conventional synthesis under the umbrella of environmentally greener and safer processes. The synthesized compounds are found to be active against tested pathogens. The above results of antifungal and antibacterial screening establish the fact that thiadiazole substituted indole derivatives can be studied further to explore out newer antimicrobial compounds.



---

*Source: 848543-2014-01-30.xml*